Gastroenterology

Lack of Biosimilar Knowledge for IBD Ranks Among Providers' Main Concerns

March 6th 2020

By Skylar Jeremias

Only 24% of providers were comfortable with prescribing biosimilars for patients with inflammatory bowel disease (IBD).

Researchers Suspect Link Between Missing Gut Microbes, Ulcerative Colitis

February 25th 2020

By Skylar Jeremias

The study compared the stool samples of patients with ulcerative colitis (UC) with patients with familial adenomatous polyposis. Both groups may have colectomies, but only the patients with UC have inflammation that may return even after surgery.

The Top 5 Biosimilars Articles for the Week of February 17

February 21st 2020

The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.

Evidence Supports the Use of Anti-TNF Biosimilars for IBD, Review Says

February 18th 2020

By Deana Ferreri, PhD

Because of the high cost of biologics, the authors recognized a need to provide access to evidence-based information on biosimilars for healthcare providers working with patients with inflammatory bowel disease.

Nonprofit Payer Says It Saved $1.7 Million Through Use of Infliximab Biosimilars

January 22nd 2020

By The Center for Biosimilars Staff

Health New England says it achieved 93% utilization by requiring prior authorization.

Survey Finds Asian Gastroenterologists Report Less Confidence in Biosimilars

January 8th 2020

By Mary Caffrey

Just 6% of the Asian doctors said they felt confident using biosimilars in clinical practice. A survey of European doctors found a similar confidence level in 2013, but that level had climbed to 28.8% by 2015.

Swiss IBD Group's Position Statement on Biosimilars Discourages Pharmacy-Level Substitution and Nonmedical Switching

January 2nd 2020

By Kelly Davio

The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).

Risk of New IBD Rises for Patients Treated With Etanercept

January 1st 2020

By Kelly Davio

While anti–tumor necrosis factor (anti-TNF) drugs are effective at treating a range of inflammatory diseases, some limited data suggest that they may, paradoxically, result in a higher risk of developing other de novo inflammatory conditions.

Switching Back to Reference Infliximab From Biosimilar Appears Effective for Patients With IBD

December 27th 2019

By Kelly Davio

At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.

Post-Induction Levels of MMP3 Can Predict Loss of Response to Infliximab in IBD

December 23rd 2019

By Kelly Davio

It has been hypothesized that metalloproteinases, and particularly MMP3, could a have a role in degrading anti–tumor necrosis factor drugs, leading to treatment failure in patients with inflammatory bowel disease (IBD).